QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
10,597 shs
Market Capitalization
$4,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

KLDO stock logo

About Kaleido Biosciences (NASDAQ:KLDO) Stock

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

June 3, 2023 | benzinga.com
Kaleido Creative Studio Launches OnNiche™: A Niche-Based Marketing System for Financial Advisors
April 26, 2023 | finanznachrichten.de
KALEIDO INTELLIGENCE LIMITED: Kaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028
June 7, 2023 | Legacy Research (Affiliate) (Ad)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
April 26, 2023 | tmcnet.com
Kaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028
March 28, 2023 | marketwatch.com
Consumer & IoT Mobile Roaming Data Traffic Expected to Triple 2019 Volume, Approaching 3,000 Petabytes in 2023: Kaleido Intelligence
February 22, 2023 | yahoo.com
Direct-To-Satellite Communications to Generate $9 Billion in Airtime Revenues for Operators in 2030: Kaleido Intelligence
January 27, 2023 | yahoo.com
Kaleido will compensate all fraudulent withdrawals from its clients' accounts
December 17, 2022 | seekingalpha.com
KLDO Kaleido Biosciences, Inc.
June 7, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
November 10, 2022 | technews.tmcnet.com
VoLTE Roaming Readiness Ranked As High Priority For Mobile Operators: Kaleido Q3 2022 Mno Survey
September 27, 2022 | tmcnet.com
Syniverse Earns Industry Honors in Roaming and Data & Financial Clearing from Kaleido Intelligence
September 12, 2022 | benzinga.com
Airlinq, Tata Communications and Giesecke+Devrient, Recognised as Champion Cellular IoT Connectivity Vendors by Kaleido Intelligence
September 5, 2022 | benzinga.com
Exclusive Free Roaming Insights Available as Kaleido Becomes GSMA Member
August 23, 2022 | yahoo.com
IPX Networks to Carry 1,900 Petabytes of Consumer & IoT Roaming Data Traffic in 2022: Kaleido Intelligence
July 26, 2022 | apnews.com
BCE To Provide $5 Billion Operator Revenue Opportunity From Permanently Roaming IoT Devices Over the Next 5 Years: Kaleido Intelligence
July 21, 2022 | msn.com
Ethereum’s Kaleido Collaborates With Polygon for Web3 Adoption
June 14, 2022 | morningstar.com
Kaleido Biosciences Inc - Stock Price vs Fair Value KLDO
June 7, 2022 | tmcnet.com
Security and Design are the biggest knots to untangle, according to the largest-ever IoT connectivity survey run by Kaleido Intelligence
May 16, 2022 | uk.finance.yahoo.com
Kaleido Biosciences, Inc. (KLDO)
April 15, 2022 | seekingalpha.com
ATER, HNRG and AGLE among mid-day movers
April 11, 2022 | benzinga.com
Kaleido Biosciences Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Kaleido Biosciences, Inc.
April 8, 2022 | benzinga.com
Kaleido Biosciences Shares Halted On Code News Pending
April 8, 2022 | finance.yahoo.com
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
April 8, 2022 | msn.com
Flagship’s Kaleido Biosciences shuts down, as more biotechs lay off staff
April 8, 2022 | seekingalpha.com
Kaleido Biosciences to delist from Nasdaq as business operations end
April 8, 2022 | bizjournals.com
Kaleido Biosciences shuts down
April 1, 2022 | finance.yahoo.com
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
See More Headlines


KLDO Company Calendar

Last Earnings
11/01/2021
Today
6/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KLDO
CUSIP
N/A
CIK
1751299
Web
www.kaleido.com
Phone
(617) 674-9000
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.10 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
42,623,000
Free Float
38,787,000
Market Cap
$4,000.00
Optionable
Not Optionable
Beta
-0.06

Key Executives

  • Ms. Kimberly Hocknell
    Sr. VP of Technical Operations
  • Ms. Susan Stewart J.D. (Age 62)
    L.L.M., Chief Regulatory Affairs – Advisor
  • Dr. Mark A. Wingertzahn Ph.D. (Age 51)
    Sr. VP of R&D and Head of Devel.

Key Competitors

View All Competitors













KLDO Stock - Frequently Asked Questions

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The firm earned $0.10 million during the quarter, compared to the consensus estimate of $0.25 million.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How do I buy shares of Kaleido Biosciences?

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Kaleido Biosciences make?

Kaleido Biosciences (NASDAQ:KLDO) has a market capitalization of $0.00 and generates $1.10 million in revenue each year.

How can I contact Kaleido Biosciences?

The official website for the company is www.kaleido.com. The company can be reached via phone at (617) 674-9000.

This page (NASDAQ:KLDO) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -